Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMRANASDAQ:EYENNASDAQ:GNPXNASDAQ:WINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRABiomerica$3.34+4.4%$3.56$1.93▼$10.16$8.50M0.34278,372 shs6,197 shsEYENEyenovia$2.97+21.7%$1.64$0.85▼$124.80$8.56M1760,693 shs1.20 million shsGNPXGenprex$0.31+5.4%$0.28$0.22▼$3.97$8.56M-0.413.89 million shs361,539 shsWINTWindtree Therapeutics$0.60+1.4%$0.93$0.52▼$737.44$2.20M0.771.25 million shs2.28 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRABiomerica+4.37%-2.34%-8.24%-36.48%-27.64%EYENEyenovia+21.72%-31.25%+162.83%+78.92%-94.12%GNPXGenprex+5.45%-0.39%+24.51%-9.47%-85.82%WINTWindtree Therapeutics+1.35%+7.70%-27.54%-66.67%-99.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMRABiomerica0.3018 of 5 stars0.03.00.00.01.90.80.0EYENEyenovia0.4712 of 5 stars1.02.00.00.01.90.01.3GNPXGenprex1.3114 of 5 stars0.02.00.04.71.90.01.3WINTWindtree Therapeutics1.6708 of 5 stars3.02.00.00.02.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMRABiomerica 0.00N/AN/AN/AEYENEyenovia 2.00Hold$2.00-32.66% DownsideGNPXGenprex 0.00N/AN/AN/AWINTWindtree Therapeutics 2.00Hold$350.0058,233.33% UpsideCurrent Analyst Ratings BreakdownLatest WINT, EYEN, GNPX, and BMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025EYENEyenoviaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMRABiomerica$5.68M1.50N/AN/A$0.39 per share8.56EYENEyenovia$67.06K127.68N/AN/A$16.32 per share0.18GNPXGenprexN/AN/AN/AN/A$4.99 per shareN/AWINTWindtree TherapeuticsN/AN/AN/AN/A$10.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMRABiomerica-$5.98M-$2.32N/A∞N/A-100.52%-90.19%-64.54%8/26/2025 (Estimated)EYENEyenovia-$27.26M-$58.40N/AN/AN/A-114,639.41%-1,108.24%-139.36%8/11/2025 (Estimated)GNPXGenprex-$30.86MN/A0.00N/AN/AN/A-409.48%-269.17%8/8/2025 (Estimated)WINTWindtree Therapeutics-$20.29M-$823.47N/AN/AN/AN/A-362.76%-79.65%8/18/2025 (Estimated)Latest WINT, EYEN, GNPX, and BMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025EYENEyenovia-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million5/15/2025Q1 2025WINTWindtree Therapeutics-$39.00-$4.63+$34.37-$4.63$2.20 millionN/A5/12/2025Q1 2025GNPXGenprex-$0.82-$0.26+$0.56-$0.26N/AN/A4/14/2025Q3 2025BMRABiomericaN/A-$0.48N/A-$0.06N/A$1.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMRABiomericaN/AN/AN/AN/AN/AEYENEyenoviaN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/AWINTWindtree TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMRABiomericaN/A3.172.22EYENEyenovia0.580.740.55GNPXGenprexN/A0.860.86WINTWindtree TherapeuticsN/A0.270.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMRABiomerica22.28%EYENEyenovia25.84%GNPXGenprex14.05%WINTWindtree Therapeutics29.33%Insider OwnershipCompanyInsider OwnershipBMRABiomerica15.00%EYENEyenovia7.10%GNPXGenprex8.47%WINTWindtree Therapeutics0.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMRABiomerica602.55 million15.59 millionOptionableEYENEyenovia402.88 million1.29 millionOptionableGNPXGenprex2027.82 million7.79 millionNo DataWINTWindtree Therapeutics303.66 million11.01 millionNot OptionableWINT, EYEN, GNPX, and BMRA HeadlinesRecent News About These CompaniesShort Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Expands By 70.4%June 17 at 1:49 AM | americanbankingnews.comWindtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B StudyJune 16 at 9:21 AM | manilatimes.netWindtree Therapeutics Receives $7 Million Offer for Preclinical Oncology PlatformJune 14 at 3:17 PM | msn.comWindtree Therapeutics: Windtree Receives Offer for Its Preclinical Oncology Drug CandidateJune 13, 2025 | finanznachrichten.deWindtree Receives Offer for Its Preclinical Oncology Drug CandidateJune 11, 2025 | tmcnet.comWindtree Therapeutics, Inc. Secures $7 Million Up Front for Preclinical Oncology Drug Candidate, Potentially Worth $130 Million in Milestones and $1.5 Billion in RoyaltiesJune 11, 2025 | quiverquant.comWorking to clean up its finances, Windtree Therapeutics gets into the garbage businessJune 10, 2025 | bizjournals.comWindtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services BusinessJune 10, 2025 | tmcnet.comWindtree Therapeutics to acquire Titan Environmental ServicesJune 10, 2025 | msn.comWINT stock touches 52-week low at $0.75 amid steep annual declineMay 24, 2025 | uk.investing.comWindtree Therapeutics Advances Istaroxime Cardiogenic Shock Program with SEISMiC C Study Interim Analysis Planned for July 2025May 22, 2025 | quiverquant.comWindtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025May 22, 2025 | globenewswire.comWindtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure ConferenceMay 19, 2025 | manilatimes.netWindtree Therapeutics to Present Istaroxime Data at European Society of Cardiology Heart Failure 2025 ConferenceMay 19, 2025 | quiverquant.comWindtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business UpdatesMay 16, 2025 | finanznachrichten.deWindtree Therapeutics announces resale of 42.17M shares by selling stockholdersMay 16, 2025 | msn.comWindtree Therapeutics Announces Positive Results on Istaroxime and SERCA2a Activator in Reducing Arrhythmias at ESC Heart Failure CongressMay 13, 2025 | nasdaq.comWindtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025May 12, 2025 | globenewswire.comWindtree Therapeutics Unveils U.S. Exclusivity Strategy for IstaroximeMay 10, 2025 | msn.comWindtree Therapeutics Announces Strategic Pathway for 7.5 Years of U.S. Exclusivity for Istaroxime in Cardiogenic ShockMay 8, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeWINT, EYEN, GNPX, and BMRA Company DescriptionsBiomerica NASDAQ:BMRA$3.34 +0.14 (+4.38%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$3.22 -0.12 (-3.71%) As of 06/16/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Eyenovia NASDAQ:EYEN$2.97 +0.53 (+21.72%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$3.00 +0.03 (+1.01%) As of 06:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Genprex NASDAQ:GNPX$0.31 +0.02 (+5.45%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$0.29 -0.02 (-5.78%) As of 06:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Windtree Therapeutics NASDAQ:WINT$0.60 +0.01 (+1.35%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$0.60 +0.00 (+0.50%) As of 06:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
